CYP2W1: Key Enzyme in Metabolism and Disease (G54905)

Target Name: CYP2W1

NCBI ID: G54905

CYP2W1

CYP2W1: Key Enzyme in Metabolism and Disease

CYP2W1, also known as CYP2W1A, is a member of the cytochrome P450 (CYP) family 2 subfamily W member 1. It is a widely expressed gene that is found in most organisms, including humans. CYP2W1 is a key enzyme in the synthesis of various metabolites, including drugs, toxins, and other substances that are produced by the liver.

One of the primary functions of CYP2W1 is to metabolize drugs that are administered to humans. Many drugs, including statins, antidepressants, and opioids, are metabolized by CYP2W1 and other enzymes in the liver. The rate at which these drugs are metabolized can have a significant impact on their effectiveness and potential side effects.

CYP2W1 is also involved in the synthesis of other metabolites, including some drugs that are used to treat diseases such as cancer and HIV. It is also involved in the production of aromaticametabolites, which are metabolites that are derived from the amino acid tryptophan.

Another function of CYP2W1 is to regulate the levels of different metabolites in the body. For example, CYP2W1 is involved in the metabolism of the amino acid tyrosine, which is a precursor to many neurotransmitters, including dopamine and norepinephrine.

CYP2W1 is also involved in the regulation of inflammation. It is has been shown to play a role in the production of pro-inflammatory cytokines, such as TNF-alpha and IL-1.

CYP2W1 is a potential drug target because of its involvement in the metabolism of drugs and other substances. By targeting this enzyme, researchers can develop new treatments for a variety of diseases. For example, inhibiting the activity of CYP2W1 could be a potential treatment for addiction, as it has been shown to play a role in the production of drugs such as methamphetamine.

Another potential application of CYP2W1 as a drug target is the treatment of chronic pain. Many drugs that are used to treat chronic pain, such as nonsteroidal anti-inflammatory drugs (NSAIDs), have been shown to increase the activity of CYP2W1. By inhibiting the activity of CYP2W1, researchers could develop new treatments for chronic pain that are less likely to have side effects.

In addition, CYP2W1 may also be a potential biomarker for some diseases. The expression of CYP2W1 has been shown to be elevated in the liver of individuals with certain diseases, such as cancer and HIV. This suggests that CYP2W1 may be a useful biomarker for the diagnosis and monitoring of these diseases.

Overall, CYP2W1 is a complex enzyme that is involved in the metabolism of a wide variety of substances in the body. Its functions include the synthesis of drugs, toxins, and other substances, as well as the regulation of inflammation and the production of metabolites. As a result, CYP2W1 is a potential drug target and a useful biomarker for the diagnosis and treatment of many diseases.

Protein Name: Cytochrome P450 Family 2 Subfamily W Member 1

Functions: A cytochrome P450 monooxygenase that may play a role in retinoid and phospholipid metabolism (PubMed:22591743, PubMed:26936974). Catalyzes the hydroxylation of saturated carbon hydrogen bonds. Hydroxylates all trans-retinoic acid (atRA) to 4-hydroxyretinoate and may regulate atRA clearance. Other retinoids such as all-trans retinol and all-trans retinal are potential endogenous substrates (PubMed:26936974). Catalyzes both epoxidation of double bonds and hydroxylation of carbon hydrogen bonds of the fatty acyl chain of 1-acylphospholipids/2-lysophospholipids. Can metabolize various lysophospholipids classes including lysophosphatidylcholines (LPCs), lysophosphatidylinositols (LPIs), lysophosphatidylserines (LPSs), lysophosphatidylglycerols (LPGs), lysophosphatidylethanolamines (LPEs) and lysophosphatidic acids (LPAs) (PubMed:22591743). Has low or no activity toward 2-acylphospholipids/1-lysophospholipids, diacylphospholipids and free fatty acids (PubMed:26936974, PubMed:22591743). May play a role in tumorigenesis by activating procarcinogens such as aflatoxin B1, polycyclic aromatic hydrocarbon dihydrodiols and aromatic amines (PubMed:20805301, PubMed:16551781, PubMed:24278521). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) (PubMed:22591743, PubMed:26936974)

The "CYP2W1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP2W1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets